IP Library Granted Patent US 9,234,179
Granted Patent B2
US 9,234,179 · App. 13/516,530 · Granted Jan 12, 2016

Materials and methods for generating pluripotent stem cells

Inventors: Lihe Guo (Shanghai, CN); Tianjin Liu (Shanghai, CN)
Assignees: SHANGHAI ICELL BIOTECHNOLOGY CO., LTD.; SHANGHAI UNITED STEM CELL BIOTECHNOLOGY CO., LTD.
C12N5/0696C12N5/06C12N5/0606C12N5/0625C12N2500/84C12N2501/115C12N2501/235C12N2502/025C12N2506/09C12N2506/13C12N2506/1307
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,234,179
App. No.
13/516,530
Granted
Jan 12, 2016
Kind
B2
Abstract

The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells.

Claims (7)

1. A method for obtaining human induced pluripotent stem cells comprising culturing human adult skin fibroblast cells on a feeder layer of human amniotic epithelial cells for a period of time sufficient to reprogram the adult skin fibroblast cells into human induced pluripotent stem (iPS) cells.

2. The method of claim 1 , wherein the amniotic epithelial cells have been cultured for fewer than 6 serial passages (P 0 -P 5 ).

3. The method of claim 2 , wherein the amniotic epithelial cells are newly isolated P 0 amniotic epithelial cells.

4. The method of claim 1 , wherein the amniotic epithelial cells are cultured in KO-DMEM medium.

5. The method of claim 4 , wherein the KO-DMEM medium comprises basic fibroblast growth factor (bFGF), human umbilical serum, newborn bovine serum, fetus bovine serum and Leukemia Inhibitor Factor (LIF).

6. The method of claim 5 , wherein the KO-DMEM comprises 10 ng/ml bFGF, 5% human umbilical serum and 12 ng/ml LIF.

7. The method of claim 1 , wherein the human iPS cells express at least one stem cell-specific marker selected from the group consisting of Oct-4, Sox-2, Rex-1, telomerase reverse transcriptase (TERT), Nanog, LIN28, SSEA-4, KLF-4, and C-MYC.

Assignments (3)
CHANGE OF NAME Recorded Oct 2, 2013
From: SINO-AMERICAN UNITED (SHANGHAI) BIOTECHNOLOGY INSTITUTE CO., LTD.
To: SHANGHAI UNITED STEM CELL BIOTECHNOLOGY CO., LTD.
Reel/Frame 031332/0784 →
CHANGE OF NAME Recorded Oct 2, 2013
From: SINO-AMERICAN ICELL (SHANGHAI) BIOTECHNOLOGY CO., LTD.
To: SHANGHAI ICELL BIOTECHNOLOGY CO., LTD.
Reel/Frame 031332/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2012
From: GUO, LIHE; LIU, TIANJIN
To: SINO-AMERICAN ICELL (SHANGHAI) BIOTECHNOLOGY CO., LTD.; SINO-AMERICAN UNITED (SHANGHAI) BIOTECHNOLOGY INSTITUTE CO., LTD.
Reel/Frame 028401/0869 →
Continuity (1)
Related Publication 20120269782A1 · Oct 25, 2012